Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4103/0028-3886.279662 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Lisocabtagene Maraleucel for Relapsed/Refractory Large B-Cell Lymphoma: A Cell Therapy Consortium Real-World Analysis.
Blood Adv
December 2024
University of Pennsylvania, Philadelphia, Pennsylvania, United States.
Lisocabtagene maraleucel (liso-cel) is an autologous CD19-directed CAR T cell therapy approved for the treatment of relapsed/refractory large B-cell lymphoma (LBCL). We present a multicenter retrospective study evaluating safety, efficacy, and resource utilization of liso-cel in the standard-of-care setting. Patients received commercial liso-cel at 7 US medical centers and patient selection, toxicity management, and disease assessment followed institutional practices.
View Article and Find Full Text PDFAn unmet need exists for patients with relapsed/refractory (R/R) follicular lymphoma (FL) and high-risk disease features, such as progression of disease within 24 months (POD24) from first-line immunochemotherapy or disease refractory to both CD20-targeting agent and alkylator (double refractory), due to no established standard of care and poor outcomes. Chimeric antigen receptor (CAR) T cell therapy is an option in R/R FL after two or more lines of prior systemic therapy, but there is no consensus on its optimal timing in the disease course of FL, and there are no data in second-line (2L) treatment of patients with high-risk features. Lisocabtagene maraleucel (liso-cel) is an autologous, CD19-directed, 4-1BB CAR T cell product.
View Article and Find Full Text PDFCost-effectiveness of second-line lisocabtagene maraleucel in relapsed or refractory diffuse large B-cell lymphoma.
Blood Adv
January 2024
Division of Medical Oncology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA.
Article Synopsis
- Lisocabtagene maraleucel (liso-cel) is a CAR T-cell therapy approved in 2022 for treating refractory diffuse large B-cell lymphoma (DLBCL) after first-line therapy, based on positive outcomes from the TRANSFORM study.* -
- A cost-effectiveness analysis showed liso-cel has an incremental cost-effectiveness ratio (ICER) of $99,669 per quality-adjusted life-year (QALY), making it cost-effective under the $100,000 QALY benchmark, though some scenarios exceed this.* -
- The analysis highlights the need to consider productivity losses to better assess the societal value of such treatments, indicating that while liso-cel has clinical
Chimeric Antigen Receptor T-Cell (CAR T-Cell) Therapy for Primary and Secondary Central Nervous System Lymphoma: A Systematic Review of Literature.
Clin Lymphoma Myeloma Leuk
January 2023
Department of Medicine, Division of Hematology/Oncology, University of Arizona, Tucson, AZ.
Relapsed/refractory central nervous system (CNS) lymphoma, whether primary or secondary, is associated with poor prognosis with currently available treatment modalities, including high-dose chemotherapy-autologous stem cell transplantation. The pivotal ZUMA-1 and JULIET trials that led to FDA approval of Axicabtagene ciloleucel and Tisagenlecleucel for relapsed refractory large cell lymphoma excluded patients with CNS involvement due to concerns of increased toxicity. However, TRANSCEND study for Lisocabtagene maraleucel in relapsed refractory large cell lymphoma allowed patients with CNS involvement and reported manageable CNS toxicities in these patients.
View Article and Find Full Text PDFThe autologous anti-CD19 chimeric antigen receptor (CAR) T-cell product, lisocabtagene maraleucel (liso-cel), is administered at equal target doses of CD8 and CD4 CAR T cells. This analysis assessed safety and efficacy of liso-cel in Japanese patients with relapsed or refractory (R/R) aggressive large B-cell lymphoma (LBCL) in Cohort 3 of TRANSCEND WORLD (NCT03484702). Liso-cel (100 × 10 total CAR T cells) was administered 2-7 days after lymphodepletion.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!